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Since its foundation in 2002, Experi-
mental and Clinical Sciences (EXCLI Jour-
nal) published more than 760 original articles 
and reviews, particularly in the field of cancer 
research (Abbastabar et al., 2018; Nojadeh et 
al., 2018; Karimian et al., 2018), cell biology 
(Li et al., 2017; Niknami et al., 2017; Ahmadi 
et al., 2017), toxicology (Randjelovic et al., 
2017; Hassani et al., 2018; Nakhaee and 
Mehrpour, 2018), neurosciences (Farajdokht 
et al., 2017; Ebrahimi et al., 2017), drug dis-
covery (Li et al., 2018; Khedher et al., 2017) 
and immunology (Fahimi et al., 2018; Sarvari 
et al., 2018). However, the editors are keen to 
keep a broad view of science and technology 
and also welcome manuscripts from other 
fields of life sciences and interdisciplinary 
studies. Our main criterion during the review 
process is the scientific quality of the study. 
Editors and reviewers focus particularly on 
whether the methods are sufficiently de-
scribed, results are presented in a transparent 
way, have been sufficiently reproduced in in-
dependent experiments and justify the main 
conclusions. If this is the case, also confirma-
tory studies or studies reporting negative re-
sults may be published. Each manuscript 
should include a statement on the aim of the 
study and convincingly explain why the ex-
periments are relevant. While a high degree of 
novelty is welcome, it is not our most im-
portant criterion in selecting manuscripts for 
publication.  
 
Improvement of the peer review process 
Sometimes authors complain about the 
length of our review process. In 2019 mean 
time periods were 19 days from submission to 
decision, and 61 days from submission to 
publication, which may be above the average 
of other journals in this field of research. Nev-
ertheless, our main challenge in future will be 
to improve the quality of the review process 
and less to enhance its speed. It is sometimes 
difficult to find competent reviewers; rela-
tively often review requests have to be sent 
repeatedly, because the quality of a review is 
not sufficient. Nevertheless, with meanwhile 
approximately 100 articles published per year 
our resource of reviewers is constantly grow-
ing. It is very important for the quality of the 
review process that authors of EXCLI Journal 
accept our invitations as peer reviewers when 
manuscripts in their field of expertise are sub-
mitted.  
 
Publish your raw data 
Publication of raw data is not yet obliga-
tory but reviewers request more frequently 
that the raw data should be made available in 
an additional electronic supplement. Raw data 
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is currently published by an increasing frac-
tion of articles (e.g. Hessel-Pras et al., 2018; 
Yaripour et al., 2018; Kang et al., 2018). In 
future, the editors will even more rigorously 
control the quality of raw data to make sure 
that they are clearly assigned to the main fig-
ures and tables and sufficiently explained in 
legends. Typically, our reviewers asked for 
supplemental raw data in case of (1) animal 
experiments where the results of each individ-
ual animal must be presented; (2) articles 
where only representative results are shown in 
the main part. This is often the case for ‘rep-
resentative’ Western blots. In such cases, we 
ask to present all blots of the independent ex-
periments in the supplement. Usually, the 
full-length Western blots must be shown; (3) 
in case of studies with humans, authors must 
accept that anonymized raw data has to be 
published in a supplement. Of course, any in-
formation that reveals the identity of an indi-
vidual will not be published. However, EX-
CLI Journal expects that e.g. a table with pa-
tient number, age (only years), male/female, 
and blood concentrations of a cytokine (or a 
similar piece of information) will be made 
available to our readers. Omics data (e.g. 
RNA-seq raw data) has to be made available 
in the established public databases.  
 
Retractions and editorial strategies against 
scientific misconduct 
Although the majority of submissions to 
EXCLI Journal is sound, we unfortunately in-
creasingly receive faked manuscripts. For ex-
ample, in 2018 and 2019 we received several 
series of more than ten manuscripts in rela-
tively short periods of time that were formally 
professionally prepared, included a similar set 
of techniques and were presented in a similar 
image format. When reviewers identified sus-
picious data patterns, we asked all corre-
sponding authors for raw data and despite of 
several initiatives never received any re-
sponse. Of course, all these manuscripts were 
rejected and are kept on file. In a further sad 
case, a scientist, who acted as a reviewer for 
another journal, submitted the reviewed and 
rejected manuscript (written by other authors) 
to our journal (under his authorship). As soon 
as this case was reported, the manuscript was 
of course retracted. Moreover, another author 
copied and pasted parts of an already pub-
lished review of other authors and submitted 
the faked manuscript to us. Since we did not 
yet routinely use plagiarism software in these 
days, the copy-paste-plagiarism was unfortu-
nately not detected by the editors and review-
ers and the review had to be rejected after 
publication. The editors of EXCLI Journal are 
sometimes surprised by the lack of foresight; 
even if a forged manuscript passes our con-
trols, it will certainly be identified by readers 
and subsequently be retracted.  
 
No fees for authors and readers 
EXCLI Journal does not take any fees 
from authors, nor fees from readers accessing 
the published papers. Therefore, we have to 
manage the journal with fewer resources com-
pared to commercial publishing houses and 
depend on the collaboration of members of 
the scientific community. If you wish to join 
the board of reviewers or editors, please do 
not hesitate to send your CV and list of publi-
cations for evaluation.  
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